Aclaris Therapeutics Touts ATI-052 Potential for 3-Month Dosing, More Phase 1 Data Incoming

Key Points

• Aclaris says lead biologic ATI-052 shows potential for three-month dosing based on SAD/MAD data and will report two–three additional cohorts later this month while running phase 1b studies in severe atopic dermatitis and asthma with a phase 2b asthma study planned around year‑end/turn of the year.
• ATI-052 is a TSLP and IL-4R bispecific that the company claims is ~70x more potent than tezepelumab and ~4x more potent than the combination of dupilumab plus tezepelumab in their testing, with healthy‑volunteer PD readouts showing near‑complete inhibition of TSLP and downstream IL‑4/IL‑13 activity.
• Safety signals to date include no conjunctivitis in SAD/MAD healthy volunteers and phase 1b AD readouts expected by year‑end; Aclaris is also advancing small molecules such as ATI‑2138 (dual ITK/JAK3) targeting alopecia, lichen planus and related indications.

Aclaris Therapeutics NASDAQ: ACRS used an H.C. Wainwright inflammatory skin diseases conference fireside chat to outline development plans and differentiation points for its lead biologic candidate, ATI-052, and to provide updates on its small-molecule pipeline.

ATI-052: bispecific approach and early clinical profile

CEO Neal Walker said the company is “really excited about 052” and highlighted previously disclosed single-ascending dose (SAD) and multiple-ascending dose (MAD) data that management believes support less frequent dosing. Walker said the data show the “potential for three-month dosing interval and PD effect that would put it in a best-in-class category.” He added that Aclaris plans to report “two additional cohorts… or three additional cohorts” later in the month as a final update from the SAD/MAD program.

Walker also said two phase 1b studies are ongoing, one in “severe atopic dermatitis” and one in asthma. He noted the company has previously communicated plans to advance into a phase 2b asthma study as “the first larger study with that construct.”

Rationale: targeting TSLP and IL-4R for broader TH2 pathway inhibition

Discussing the scientific rationale for ATI-052, a company representative identified as “Operator” described the molecule as a TSLP and IL-4 receptor (IL-4R) bispecific antibody. The speaker said the program combines a TSLP antibody with “a very long retention time” and “the best potency in the class” tested by the company, which they characterized as “70 times more potent than tezepelumab.”

On target selection, the same speaker said IL-4R was chosen because IL-4 and IL-13 “both drive TH2 disease,” and inhibiting the receptor can neutralize the impact of both cytokines rather than “leaving IL-4 on the table.” The company’s representative said healthy volunteer data showed “100% inhibition of TSLP activity and IL-4 and IL-13 activity downstream” based on chemokine secretion readouts.

In comparing ATI-052 with established therapies, the speaker said the company believes the bispecific has synergy relative to monotherapies such as tezepelumab (“Tezi”) and dupilumab (“Dupie”), and stated the bispecific was “4 times more potent than the combination of Dupie plus Tezi combined” in the company’s testing.

Expectations for efficacy, itch endpoints, and durability

Asked about potential clinical impacts on standard atopic dermatitis measures such as IGA and EASI, the company’s representative said targeting TSLP “at the top of the TH2 cascade” could support activity beyond more narrowly targeted approaches. The speaker cited dupilumab performance as context, describing “two-thirds of patients with a 75% response in EASI” and IGA 0/1 responses of “35% to 40%,” and said Aclaris is “expecting to see a much more enhanced activity profile,” including “early and late durability of activity.”

On trial endpoints, the representative emphasized itch as a key focus, saying itch is “the main symptom” and early itch relief can allow skin healing and reduce inflammation. The speaker said Aclaris will evaluate “both EASI and itch in tandem” and look for not just incremental gains, but “something… a lift in terms of that efficacy,” along with a faster onset of benefit to address flare-driven disease. The company selected an “eight-week primary” endpoint and will follow patients for “10 weeks post” the Day 57 primary endpoint, noting the first atopic dermatitis study is enrolling “all severe patients.”

Dosing and molecule design: half-life, binding architecture, and device plans

Aclaris also focused on dosing convenience. The company’s representative said ATI-052 demonstrated a “26-day half-life as a minimum,” and that MAD accumulation data “predicts more of a greater than 40-day half-life.” The speaker said the half-life is “at least three times” that of dupilumab, supporting the potential for “two to three months” between doses from a pharmacokinetic perspective.

Pharmacodynamics were also cited, with the company describing “up to three weeks of 100% inhibition” in a TARC-based readout following IL-4 or TSLP stimulation. The speaker said Aclaris believes its MAD cohorts can support “three-month dosing with substantial inhibition” of both the upstream TSLP target and downstream IL-4/IL-13 activity.

Walker added that, from a commercial perspective, moving from dosing intervals such as every two weeks to monthly or longer could be meaningful, and he described “Q3 months” as a practical “sweet spot” for certain inflammatory diseases with flare and quiescent periods.

On device presentation, Aclaris said it is pursuing formulations that could enable options similar to those available for dupilumab, including prefilled syringes and pen-style injectors.

In discussing competition from multi-specific antibodies, the company’s representative described ATI-052 as having “four independent binding sites,” including “two to TSLP and two to IL-4 receptor,” with divalent binding to each target. The speaker said the TSLP portion binds across the “N- and C-terminus” and cited a “400-hour residence time” on TSLP, while also pointing to a YTE half-life extension as a potential advantage.

Safety observations and pipeline expansion, including small molecules

On safety, Selvaraju noted that no conjunctivitis was observed in SAD/MAD healthy volunteer cohorts. Walker said the company hopes to continue seeing “no conjunctivitis or very little,” and the company’s representative added that the cause of conjunctivitis in IL-4/IL-13 pathway inhibition “is really hard to nail down,” but suggested the TSLP component might help “offset” effects at the top of the cascade. The company said phase 1b data in atopic dermatitis are expected “by the end of the year.” Walker also said he was “not aware of a very high risk” regarding cutaneous T-cell lymphoma, noting that ATI-052 is “a different construct” than dupilumab.

Beyond ATI-052, Walker said Aclaris has an ongoing study with a standalone TSLP monoclonal antibody and expects a readout “towards the back part of the year.” He said that as the bispecific generates data, the company expects to invest more heavily there, and reiterated plans to initiate a phase 2b asthma study “at the turn of the year.” Walker also said that after the SAD/MAD dataset, the program has “generated interest,” and he discussed how partnerships or a larger balance sheet could allow faster pursuit of multiple indications following proof-of-concept.

On small molecules, Walker and Chief Scientific Officer Roland Kolbeck discussed ATI-2138, described as a dual ITK/JAK3 inhibitor. Kolbeck said the compound inhibits T-cell receptor signaling and also inhibits cytokines “driven by JAK3,” and argued that JAK3 and ITK are more restricted to the immune system than other JAK isoforms. Kolbeck stated ATI-2138 is “way more potent than ritlecitinib on JAK3” and “about 50-fold more potent” than a Corvus ITK inhibitor on ITK, as characterized by the company.

Walker said Aclaris is prioritizing indications that leverage ATI-2138’s dual mechanism, including alopecia, scarring alopecias, vitiligo, and lichen planus. He highlighted lichen planus as a “great mechanistic fit” and said the company is leaning toward opportunities across oral and cutaneous lichen planus and lichen planopilaris, noting “there’s nothing approved for any of them.” He said Aclaris plans to “formalize” the indication strategy “at the end of the month.”

Walker also discussed ATI-9494, described as an ITK inhibitor designed to avoid JAK3 inhibition, with the goal of delivering “JAK-like efficacy in a pill without the safety baggage,” and suggested it could potentially pursue indications similar to those targeted by dupilumab.

About Aclaris Therapeutics NASDAQ: ACRS

Aclaris Therapeutics, Inc NASDAQ: ACRS is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing novel small‐molecule therapies for dermatologic diseases and related rare disorders. The company's pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non‐melanoma skin lesions. Lead programs include ATI‐50002, a topical agent in late‐stage development for molluscum contagiosum removal; ATI‐50003 for common wart resolution; ATI‐1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI‐450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.